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ABSTRACT 
Past studies have suggested that activation of the proteolytically activated receptor (PAR-1) 
by thrombin or the peptide SFLLRNP results in decreased motoneuron survival. Although PAR-
1 appears to be the primary receptor for thrombin activation, recent studies suggest that thrombin 
may activate other PARs in the nervous system. The fact that thrombin has the ability to activate 
other receptors in a similar manner raises the question as to whether thrombin's effects are 
mediated via PAR-1 alone or in combination with additional PARs. Our results suggest that 
while activation of PARs 2, 3 and 4 do not affect cell survival, PARs 3 and 4 may alter 
morphology, thus strengthening the previous finding that thrombin-induced programmed cell 
death in the motoneuron column is mediated via PAR-1, but they also suggest alternative roles 
for PARs 3 and 4. 
INTRODUCTION 
Throughout embryonic development, various neuronal cell populations, including 
motoneurons, undergo a period of naturally occurring programmed cell death (PCD). During 
development of the chick embryo, 40-70% of postmitotic lumbar motoneurons undergo PCD 
between embryonic days (E)6 and E10 (Hamburger, 1975; Oppenheim, 1991; Clarke and 
Oppenheim, 1995), which corresponds to gestation weeks 11 to 18 in humans (Hamburger and 
Oppenheim, 1982; Forger and Breedlove, 1987). Programmed cell death is thought to remove 
aberrant neurons, correct synaptic errors, and regulate cell numbers (see Houenou and 
Oppenheim, 1994). The motoneurons that die during PCD appear to die by apoptosis (Kerr et 
al., 1972), which is characterized by cleavage at nucleosome linker regions, producing 180-200 
base pair fragments (see Lo et al, 1995). 
Furthermore, there are several motoneuron diseases marked by apoptotic-like cell death in the 
brain or spinal cord (Swash and Schwartz 1992). Such diseases include amyotrophic lateral 
sclerosis, X-linked spinal and bulbar muscular atrophies, and infantile and juvenile spinal 
muscular atrophies. Each of these diseases is characterized by muscle weakness, atrophy, and 
motoneuron loss. Furthermore, both the human protease-activated receptor-1 (PAR-1) and PAR-
2 genes are tightly linked on chromosome 5ql3, near the spinal muscular atrophy locus (Schmidt 
et al., 1997), suggesting that these receptors and their serine protease ligands may be involved in 
neurodegeneration. 
Recent studies have localized serine proteases, such as thrombin, and their receptors to 
different cellular populations within the nervous system (see Festoff et al., 1996; Turgeon and 
Houenou, 1997; Turgeon et al, 2000). While thrombin is well known for its important role in 
coagulation, it also appears to play an important role in the nervous system. Exogenous 
thrombin has been shown to alter cell morphology and differentiation in astrocyte, 
neuroblastoma, and motoneuron cultures (Gurwitz and Cunningham, 1988, 1990; Zurn et al., 
1988; Grabham et al, 1989; Suidan et al, 1992; Turgeon et al, 1998). Thrombin appears to 
exert its effects through activation of PAR-1. Activation of this receptor requires specific 
cleavage of the extracellular domain to generate a new amino terminus capable of undergoing a 
conformational change allowing it to bind to and activate the receptor. The newly generated 
amino terminus is SFLLRNP (serine-phenylalanine-leucine-leucine-arginine-asparagine-proline; 
Vu et al, 1991). Using this knowledge, we have previously shown that in ovo treatment with 
this peptide decreases motoneuron cell survival during the naturally occurring PCD (Turgeon et 
al., 1999). 
During the initial investigation of thrombin's role in programmed cell death, PAR-1 was 
thought to be the only receptor activated by thrombin. Recent studies indicate the presence of 
other proteolytically activated receptors (PARs), which may also be activated by thrombin (Cupit 
et al, 1999). These newly found receptors seem to have many similarities to PAR-1 (see 
Turgeon et al, 2000), particularly PARs 3 and 4. Furthermore, in addition to PAR-1, PAR-3 and 
PAR-4 appear to be important in thrombin-induced platelet activation (Kahn et al., 1998). All 
members of the PAR family are seven transmembrane G protein-coupled receptors; each with its 
own unique tethered ligand responsible for its receptor's activation (Smith-Swintowsky et al, 
1997; Kahn et al, 1998). Using these unique sequences, we can examine the individual 
activation of each PAR. While PAR-2 is not specifically categorized as a thrombin receptor, it 
can be activated by the PAR-1 tethered ligand, SFLLRNP. Thus, in addition to examining the 
effects of PAR-3 and 4 we also examined PAR-2 activation in our models. The purpose of this 
study was to investigate whether or not PARs besides PAR-1 play a role in thrombin-induced 
motoneuron cell death. 
METHODS AND MATERIALS 
In Ovo Treatment of Chick Embryos. Eggs were obtained from the Charles E. Morgan 
Poultry Center at Clemson University (Clemson, SC) and were incubated at 37°C and 90% 
humidity. On E4, a small circle was carefully cut from the top of the egg. Those eggs that 
contained viable embryos with blood vessels in the chorioallantoic membrane and visible 
heartbeats were then resealed with clear tape. Embryonic age was determined by the staging 
criteria established by Hamburger and Hamilton (1951). 
Beginning on E5, embryos were treated once daily with 200 ul of various stock 
concentrations of SFLLRNP (PAR-1 peptide; Bachem, King of Prussia, PA), SLIGRL (PAR-2 
peptide; Bachem), SLIGVK (PAR-3 peptide; Bachem), or GYPGKF (PAR-4 peptide; Bachem) 
to achieve final concentrations of 10 uJVI, 20 u,M, and 40 u,M. The control embryos received 200 
pi of IX phosphate-buffered saline (PBS) or 200 ul of inactive or stock antagonist peptides 
FSLLRNP (inactive PAR-1 peptide, Bachem), LSIGRL (inactive PAR-3 peptide, Bachem), 
LSIGVK (inactive PAR-3 peptide, Bachem), GAPGK (inactive PAR-4 peptide, Bachem) to 
achieve a final concentration of 40 uJVI for each treatment. 
Histological preparation and analysis. Embryos were sacrificed on E9, eviscerated, and 
trimmed to expose the intact spinal cords. The tissues were preserved overnight in Carnoy's 
fixative (150 ml glacial acetic acid, 900 ml ethanol, 450 ml chloroform) and then transferred to 
70%) ethanol. These tissues were then embedded in paraffin and serially sectioned at 10 urn 
using a rotary microtome. Finally, the sections were stained with 1% thionin and examined. 
Using criteria described by Clarke and Oppenheim (1995), lumbar motoneurons were counted. 
Motoneuron counts were performed blind on every tenth section in the lateral motor column 
throughout the entire lumbar spinal cord. Cells with a large (> 10 jam) nucleus, containing at 
least one distinct nucleolus, and a large distinctly stained cytoplasm were counted. Using these 
rather stringent criteria for cell counting, it has been shown that less than 1% of the cells appear 
on two successive sections and, therefore, only an insignificant number of cells would be 
counted twice (Oppenheim et al, 1989). 
To measure the nuclear area, a microscope equipped with a camera (Nikon Coolpix990; 3.34 
megapixels; 3X 200 zoom) captured images at 400X total magnification. These pictures were 
saved to a PowerMac computer and analyzed with NIH image 1.61. 
Motoneuron Cultures. Motoneurons were isolated from E5 chick embryos and cultured 
using modified methods from Dohrmann et al., (1986) and Arakawa et al, (1990). Briefly, the 
ventral portions of the lumbar spinal cords of chick embryos were removed using tungsten 
needles and kept in ice-chilled sterile-filtered PBS until dissections were complete. The ventral 
lumbar spinal cords, containing primarily motoneurons, were dissociated in 30 mM subermidate 
(Sigma; St. Louis, MO) for 15 minutes. The partially dissociated cells were then added to 
Lebowitz-15 (L-15; Gibco, Grand Island, NY), defined serum-free medium and further 
dissociated by running the mixture through a 1 ml pipette, followed by centrifugation (400 x g 
for 15 min; Beckman Centrifuge) over a layer of 6.8% metrizamide (Sigma). Motoneurons 
remained in the top half of the metrizamide fractions, forming a visible white band, which was 
collected and added to 5 ml of L-15 medium. A 4% bovine serum albumin cushion was then 
gently added beneath the cells and centrifuged at 200 x g for 10 min (Beckman). The 
supernatant was discarded and the pellet resuspended in 1 ml of L-15 and filtered through a 50-
mm nylon filter. A portion of this preparation was loaded onto a hemocytometer for an initial 
cell count. From this initial count, the cells were diluted appropriately in L-15 medium, 
supplemented with glutamine, glucose, sodium bicarbonate, penicillin-streptomycin, 
conalbumin, putrescine, insulin, progesterone, and sodium selenite (Sigma), and plated at a 
density of 2000 motoneurons/well in 35 mm3 petri dishes, each with four wells that were 10 mm3 
in diameter (Greiner dishes; USA Scientific, Atlanta, GA). The dishes were incubated with 
laminin (Sigma) and poly-D-ornithine (Sigma). Cells were incubated in a CO2 water-jacketed 
incubator at 37°C. Motoneurons were identified by immunostaining the cultures with SC-1 
(Microbial Strain Data Network; ECACC) a specific marker for early developing motoneurons 
(Henderson et al., 1994). After plating, the motoneurons were allowed to attach to the plate for 
two hours prior to co-treatments with 14 u,g/ml chicken muscle extract (CMX) and l-1000nM of 
SFLLRNP, FSLLRNP, SLIGRL, LSIGRL, SLIGVK, LSIGVK, GYPGKF, or GAPGKF. 
Control cultures were grown in either L-15 medium (negative control) or CMX supplemented L-
15 medium (positive control; Milligan et al, 1994). 
Cell numbers were obtained by counting the viable cells across two diameters of each culture 
well at 200X total magnification on a phase-contrast miscroscope (Unitron TCM-BR; Martin 
Mcroscopes, Easley, SC). To examine motoneuron survival, the criteria used included the 
presence of two or more neurites per neuron, with the length of at least one of those neurites 
being greater than twice the diameter of the cell soma, and the absence of cytoplasmic vacuoles 
and/or degenerating neurites (Mlligan et al., 1994). 
cAMP Assay. To determine cAMP concentrations following PAR activating peptide 
treatments, a cAMP immunoassay kit (Sigma) was used. Motoneurons were cultured as stated 
above. Twenty-four hours following culture and appropriate treatment, the media were removed 
and cells were treated with 0.1 M HC1 for 10 min. Following the HC1 incubation, the cells were 
visually examined to verify lysis. The cells were centrifuged at 1000 x g (Beckman) at room 
temperature. The supernatant was collected and used in the remainder of the assay. The cAMP 
standards (20 pmol/ml, 5 pmol/ml, 1.25 pmol/ml, 0.312 pmol/ml and 0.078 pmol/ml cAMP) and 
the samples were incubated at room temperature with primary and secondary antibodies. The 
excess reagents were removed and the enzyme substrate was added. Following incubation, the 
standards and samples were read on a microplate reader (MRX Microplate Reader, Dynatech 
Laboratories, Chantilly, VA) at 450 nm. The intensity of the yellow color was inversely 
proportional to the concentration of cAMP. The measure of optical density was then used to 
calculate the cAMP concentration. 
Statistical analysis. All data were analyzed using one-way ANO VA followed by the Tukey-
Kramer multiple comparison post hoc test, if p < 0.05. 
RESULTS 
As shown in Figure 
1, administration of the 
PAR-2, -3, or -4 syn-
thetic peptides (10, 20, 
and 40 u,M) during the 
period of PCD had no 
significant effect on the 
number of surviving 
lumbar spinal motoneu-
rons in comparison to 
PBS treated controls 
(p>0.05), whereas treat-
ments of 10-40 uM 
SFLLRNP, the PAR-1 
peptide, decreased the 
number of surviving 
neurons (p<0.001) as 
previously found by 
Turgeon et al. (1998). 
Furthermore, treat-
ments with the requisite 
inactive peptides did not 
alter motoneuron num-
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Figure 1. Motoneuron numbers (means + SEM) in the lumbar lateral 
motor column of E9 embryos following once daily treatments with 
200 \A IX PBS (control), 10-40 ^iMPAR-1, PAR-2, PAR-3 or PAR-4 
activating peptide from E5-E8. Only treatments with the PAR-1 
activating peptide decreased motoneuron cell survival in comparison 
to the control (p < 0.001; n = 8 for each group). Embryos treated with 
200 \A of 10-40 |jM of the inactive peptides for PAR-1, -2, -3, and -4 
resulted in no significant difference in the mean number of 
motoneurons in comparison to the control (p >0.05; data not shown). 
Concentrations greater than 40 uM of SLIGRL and 100 uM of SFLLRNP, SLIGKV or 
GYPGKF resulted in degeneration of the chorioallantoic vasculature and subsequent death of the 
embryos within two days of treatment (data not shown). 
Motoneuron cultures treated with SLIGRL, SLIGKV, or GYPGKF (1-1000 nM) did not 
show any signs of decreased survival in comparison to control cultures (p>0.05; Figure 2); 
whereas, identical concentrations of SFLLRNP decreased motoneuron cell survival (p<0.05) 
(Figure 2). 
To further examine the potential effects of PAR ligand administration on motoneuron vi-
ability, we measured cAMP concentrations in vitro and the nuclear area of surviving 
motoneurons in 
vivo. As shown in 
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40 uM) did not alter 
the mean nuclear 
area in comparison 
to the PBS treated 
controls (p>0.05; 
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Figure 2. Motoneuron survival (mean percentages + SEM) in 48-h 
cultures maintained in 1.5 ml of Lebowitz-15 (L-15) medium 
containing 1-lOOOnM of the PAR-1, PAR-2, PAR-3 or PAR-4 
activating peptide. Control cultures were grown L-15 medium and 
assessed at the 48-h time point. Only treatments with 10, 100, and 
1000 nM of the PAR-1 activating peptide resulted in decreased 
motoneuron cell survival (*p< 0.05; ** p< 0.01) in comparison to the 
control. Cultures maintained in 1.5 ml of L-15 containing lOOOnM of 
the inactive peptides for PAR-1, -2, -3, and -4 resulted in no 
significant difference in the mean number of motoneurons in 
comparison to the control (p >0.05; data not shown), n = 3 trials 
performed in triplicate. 
Table 1. cAMP concentrations following treatment with various PAR activating peptides 















0.030 + 0.001 








0.030 + 0.002 
Negative controls were grown in Leobowitz-15 medium 
^Positive controls were grown in Leobowitz-15 medium supplemented with 14(xg/ml of chicken 
muscle extract. 
^SFLLRNP -serine-phenylalanine-leucine-leucine-arginine-asparagine-proline 
§SLIGRL - serine-leucine-isoleucine-glycine-arginine-leucine 
"SLIGVK-serine-leucine-isoleucine-glycine-valine-lysine 
^GYPGKF -glycine-tyrosine-proline-glycine-lysine-phenyalanine 
*p<0.05 in comparison to the negative control. 
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Figure 3. Nuclear area (means + SEM) of surviving motoneurons in the lumbar lateral motor column 
of E9 embryos following once daily treatments with 200 ul IX PBS (control), 10-40 uM PAR-1, PAR-
2, PAR-3 or PAR-4 activating peptide from E5-E8. Treatment with 10 ^M of the PAR-3 activating 
peptide decreased nuclear area in comparison to the control (p<0.05) as did treatments with 20 and 40 
(jMof the PAR-1 activating peptide (p<0.05). However, treatment with 10, 20 or 40 ^M of the PAR-4 
activating peptide increased nuclear area in comparison to control (p<0.05). For each treatment, 500 
motoneurons from 5 separate embryos were measured. 
DISCUSSION 
The main goal of this experiment was to examine the effects of PAR-2, -3, and -4 activation 
in embryonic chick spinal motoneurons in vivo during PCD, and in vitro and to compare these 
results to previously published studies involving PAR-1. Our results indicate that activation of 
PAR-2, -3, or -4 does not significantly affect the viability of these neurons in vivo or in vitro. 
However, this does not rule out the presence or functionality of these receptors on motoneurons. 
While, no direct effects on motoneuron viability were seen, our results did show that the ligands 
for PARs 3 and 4 altered motoneuron nuclear area. Like SFLLRNP (Turgeon et al, 1998), 
SLIGKV decreased motoneuron nuclear area, while GYPGKF increased nuclear area. These 
results suggest that a delicate balance of serine proteases and their receptors may exist in the 
spinal cord to aid in the coordination of growth and development. This study also supports the 
conclusion from previously published papers that thrombin-induced motoneuron cell death is 
mediated via the PAR-1 receptor, since treatments with the other PAR agonists did not alter the 
survival of these cells. 
Studies conducted by Turgeon et al. (1998, 1999) suggest that the serine protease, thrombin, 
or the synthetic peptide, SFLLRNP, induce degeneration and death of avian lumbar 
motoneurons. These studies, however, did not rule out the fact that additional PARs could play a 
role in these processes. Although PARs have been initially identified and shown to play major 
roles in hemostasis and fibrinogenesis (Kahn et al, 1998), there is increasing evidence 
suggesting that these receptors have different functions in the nervous system (see Festoff et al., 
1996; Turgeon and Houenou, 1997; Turgeon et al., 2000). PAR-1 and PAR-2 are coexpressed 
by hippocampal neurons, and their activation leads to neurodegeneration (Smith-Swintowsky et 
al., 1997). In addition, it has been reported that primary mouse spinal motoneurons and a 
motoneuron cell line express PAR-1 and activation of this receptor induces cell death (Smirnova 
et al., 1998). Due to the specificity of SFLLRNP for PAR-1 (Ishihara et al, 1997), it is unlikely 
that other PARs are involved in the thrombin/SFLLRNP -induced motoneuron cell death. 
Together these results support the hypothesis that thrombin/SFLLRNP-induced motoneuron 
cell death is achieved through activation of PAR-1. Information concerning the possible role(s) 
of PARs in different areas of the nervous system may help to elucidate the mechanisms involved 
in certain neurodegenerative diseases. The developmental expression of PARs, their respective 
ligands, and their effects upon motoneuron survival may be related to neuronal cell death 
following injury and disease. 
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